Increased mechanistic target of rapamycin (mTOR) activation has been observed in the lymph nodes of patients with the iMCD-TAFRO syndrome, whereas the iMCD-TAFRO syndrome pathophysiology remains unclear. Here, MTOR is linked to Castleman-Kojima disease.